medigraphic.com
Asociación Mexicana de Gastroenterología

2005, Número 2

<< Anterior Siguiente >>

Rev Gastroenterol Mex 2005; 70 (2)


Vectores virales en terapia génica. Ventajas de los vectores adenoasociados

Sandoval RAS, Salazar MAM, Armendáriz-Borunda J

Idioma: Español
Referencias bibliográficas: 57
Paginas: 192-202
Archivo PDF: 73.89 Kb.


RESUMEN

La terapia génica se ha visto favorecida por el desarrollo de un número cada vez mayor de vectores, con el fin de lograr una expresión más persistente y una administración inocua. Dentro de los vectores virales los adenoasociados presentan ventajas prometedoras. Este virus de ADN es capaz de transducir gran variedad de líneas celulares, integrarse al genoma del huésped y lograr expresiones persistentes del transgén por lapso de meses, todo esto sin generar una respuesta inmune celular. La aplicación de nuevas metodologías en la producción y purificación de estos vectores ha mejorado considerablemente la cantidad y calidad de partículas infecciosas que se generan. En este momento, gracias a los mencionados desarrollos biotecnológicos, la terapia génica es una opción terapéutica viable para varias enfermedades crónico-degenerativas.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Vassilopoulos G, Stamatoyannopoulos G. The basics of gene therapy vectors. Haema 2000; 3: 214-28.

  2. Hillemann MR, Werner JR. Recovery of a new agent from patients with acute respiratory illness. Proc Soc Exp Biol Med 1954; 85: 183-8.

  3. Van Regenmorten MHV, Fauquet CM, Bishop DHL. Adenoviridae. In: Virus taxonomy. Seventh report of the International Committee on Taxonomy of Viruses. San Diego Academic Press; 2000, p. 227-38.

  4. Russell WC. Update in adenovirus and its vectors. J Gen Virol 2000; 81: 2573-604.

  5. García-Bañuelos J, Siller-López F, Miranda A, Aguilar LK, Aguilar-Córdova E, Armendáriz-Borunda J. Cirrhotic rat livers with extensive fibrosis can be safety transduced with clinical-grade adenoviral vectors. Evidence of cirrhosis reversion. Gene Ther 2002; 9: 127-34.

  6. Smith CA, Woodruff LS, Rooney C, Kitchingman GR. Extensive cross-reactivity of adenovirus-specific cytotoxic T cells. Hum Gen Ther 1998; 9(10): 1419-27.

  7. Amalfitano A, Hauser MA, Hu H, Serra D, Begy CR, Chamberlain JS. Production and characterization of improved adenovirus vectors with E1, E2b, and E3 gene deleted. J Virol 1998; 72: 926-33.

  8. Berns KI. Parvovirus replication. Microbiol Rev 1990; 54: 316-29.

  9. Monahan PE, Samulski J. Adeno-associated virus vectors for gene therapy: more pros than cons? Mol Med Today 2000; (6): 433-40.

  10. Weitzman M, Kyostio S, Kotin R, Owens R. Adeno-associated virus (AAV) rep proteins mediate complex formation between AAV DNA and its integration site in human DNA. PNAS 1994; 91: 5808.

  11. Berns KI, Giraud C. Biology of adeno-associated virus. Curr Top Microbiol Immunol 1996; 218: 1-23.

  12. Samulski RJ, Chang LS, Shenk T. Helper free stocks of recombinant adeno-associated viruses: normal integration does not require viral gene expression. J Virol 1989; 63: 3822-8.

  13. Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X, Samulski RJ. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol 2002; 76(2): 791-801.

  14. Zabner J, Seiler M, Walters R, Kotin RM, Fulgeras W, Davidson BL, Chiorini JA. Adeno-associated virus type 5 (AAV5) but not AAV2 binds to the apical surfaces of airway epithelia and facilitates gene transfer. J Virol 2000; 74: 3852-8.

  15. Handa A, Muramatsu S, Qiu J, Mizukami H, Brown Kevin E. Adeno-associated virus (AAV3) based vectors transduce hematopoietic cells not susceptible of transduction with AAV2 based vectors. J Gen Virol 2000; 81: 2077-84.

  16. Xiao W, Chirmule N, Berta S, McCullough B, Gao G, Wilson JM. Gene therapy vectors based on adeno- associated virus vectors type 1. J Virol 1999; 73: 3994-4003.

  17. Samulski RJ, Zhu X, Xiao X, Brook JD, Housman DE, Epstein N, Hunter LA. Targeted integration of adeno-associated virus (AAV) into human chromosome 19. EMBO J 1991; 10: 3941-50.

  18. Satoh W, Hiral Y, Tamayose K, Shimada T. Site-specific integration of an adeno-associated virus vector plasmid mediated by regulated expression of Rep based on Cre-lox P recombination. J Virol 2000; 74: 10631-8.

  19. Miao C, Snyder R, Schowalter D, Patijn G, Winther B, Kay M. The kinetics of rAAV integration in the liver. Nature Genetics 1998; 19: 13-15.

  20. Xiao W, Berta SC, Lu M, Moscioni D, Tazelaar J, Wilson J. Adeno-associated virus as a vector for liver directed gene therapy. J Virol 1998; 72: 10222-6.

  21. Chirmule N, Xiao W, Truneh A, Schnell M, Hughes J, Zoltick P, Wilson J. Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J Virol 2000; 74: 2420-5.

  22. Rusell DW, Miller AD, Alexander IE. Adeno-associated virus vectors preferentially transduce cells in S phase. PNAS 1994; 91: 8915-19.

  23. Miao CH, Nakai H, Thompson R, Storm TA, Chiu W, Snyder R, Kay M. Nonrandom transduction of recombinant adeno-associated virus vectors in mouse hepatocytes in vivo: cell cycling does not influence hepatocyte transduction. J Virol 2000; 74(8): 3793-803.

  24. Summerford C, Samulski RD. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 1438-45.

  25. Summerford C, Bartlett JS, Samulski RJ. aV-b5 integrin: A co-receptor for adeno-associated virus type 2 virions. Nature Medicine 1999; 5: 78-82.

  26. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nature Medicine 1999; 5: 71-7.

  27. Ferrari F, Samulski T, Schenk T, Samulski RJ. Second strand synthesis is a rate limiting step for efficient transduction by recombinant adeno-associated virus vector. J Virol 1996; 70(5): 3227-34.

  28. Keyun Q, Xu-Shan W, Dagmar MK, Selvarangan P, Anil B, Arun S. Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2- mediated transgen expression. PNAS 1997; 94: 10879-89.

  29. Trahair TN, Alexander IE, Rowe PB, Smythe JA. The adenovirus E4 ORF6 and E1b 55kDa proteins cooperate in a p53-independent manner to enhance transduction by recombinant adeno-associated virus vectors. J Gen Virol 2000; 81: 2983-91.

  30. Alexander IE, Rusell DW, Miller AD. DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors. J Virol 1994; 68: 8282-7.

  31. Fisher K, Gao GP, Weitzman MD, DeMateeo R, Burda J, Wilson JM. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 1996; 70: 520-32.

  32. Wheeler M, Kono H, Rusyn I, Arteel GE, McCarty D, Samulsky RJ, Thurman RG. Chronic ethanol increases adeno-associated viral transgen expression in rat liver via oxidant and NFkB-dependent mechanisms. Hepatology 2000; 32: 1000-59.

  33. Yalkinoglu A, Heilbronn R, Bürkle A, Schlehofer J, Hausen H. DNA amplification of adeno-associated virus as a response to cellular genotoxic stress. Cancer Res 1988; 48: 3123-9.

  34. Lipkowitz M, Hanss B, Tulchin N, Wilson N, Langer J, Ross M, Kurtman G, Klotman P, Klotman M. Transduction of renal cells in vitro and in vivo by adeno-associated virus gene therapy vectors. J Am Soc Nephrol 1999; 10: 1908-15.

  35. Duan D, Sharma P, Yang J, Yue Y, Dudus L, Zhang Y, Fisher K, Engelhard J. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol 1998; 72: 8568-77.

  36. Nakai H, Ytant Stephen R, Storm Theresa A, Fuess S, Meuse L, Kay M. Extracromosomal recombinant adeno-associated virus vector genomes are primarily responsible for stable liver transduction in vivo. J Virol 2001; 75(15): 6969-76.

  37. Yang J, Zhou W, Zhang Y, Zidon T, Ritchie T, Engelhardt JF. Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. J Virol 1999; 73: 9468-77.

  38. Nakai H, Storm T, Kay M. Recruitment of single-stranded recombinant adeno-associated virus vector genomes and intermolecular recombination are responsible for stable transduction of liver in vivo. J Virol 2000; 74(20): 9451-63.

  39. Auricchio A, Hildinger M, O’Connor E, Guang-Ping G, Wilson JM. Isolation of highly infectious and pure adeno-associated virus type 2 vectors with a single-step gravity-flow column. Hum Gen Ther 2001; 12: 71-6.

  40. Chao H, Mao L, Bruce AT, Walsh CE. Sustained expression of human factor VIII in mice using a parvovirus-based vector. Blood 2000; 95: 1594-9.

  41. Nakai H, Herzog R, Hagstrom N, Walter J, Kung S, Yang E, Tai S, Iwaki Y, Kurtzman G, Fisher K, Colosi P, Couto L, High K. Adeno-associated viral vector mediated gene transfer of human blood coagulation factor IX into mouse liver. Blood 1998; 91: 4600-7.

  42. Wang L, Tabake K, Bidlingmaier S, Ill C, Verma I. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy. PNAS 1999; 96: 3906-10.

  43. Jung SC, Han IP, Limaye A, Xu R, Gelderman MP, Zerfas P, Tirumalai K, Murray GJ, During MJ, Brady RO, Qasba P. Adeno-associated viral vector-mediated gene transfer results in long term enzymatic and functional correction in multiple organs of Fabry mice. PNAS 2001; 98: 2676-81.

  44. Acland G, Aguirre G, Ray J, Zhang Q, Aleman T, Cideciyan A, Pearce-Kelling S, Anand V, Zeng Y, Maguire A, Jacobson S, Hauswirth W, Bennett J. Gene therapy restores vision in a canine model of childhood blindness. Nature Genetics 2001; 28: 92-5.

  45. Limuro Y, Nishio T, Morimoto T, Nitta T, Stefanovic B, Choi SK, Brenner D, Yamaoka Y. Delivery of matrix metalloproteinase-1 attenuates established liver fibrosis in the rat. Gastroenterology 2003; 124: 445-58.

  46. Ueki T, Kaneda K, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, Matsumoto K, Nakamura T, Takahashi H, Okamoto E, Fuijimoto J. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. Nature Med 1999; 5: 226-30.

  47. Qing Yu, Rong S, Qian H, George SE, Rockey D. Gene transfer of the neuronal NO synthase isoform to cirrhotic rat ameliorates portal hypertension. JCI 2000; 105: 741-8.

  48. Salgado S, García J, Vera J, Siller F, Bueno M, Miranda A, Segura A, Grijalva G, Segura J, Orozco H, Hernández-Pando R, Fafutis M, Aguilar LK, Aguilar-Cordova E, Armendáriz-Borunda J. Liver cirrhosis is reverted by urokinase-type plasminogen activator gene therapy. Molecular Therapy 2000; 2: 545-51.

  49. Siller-López F, Sandoval A, Salgado S , Salazar A , Bueno M, García J, Vera J, Gálvez J, Hernández I, Ramos M, Aguilar-Cordova E, Armendáriz-Borunda J. Treatment with human metalloproteinase-8 gene delivery ameliorates experimental rat liver cirrhosis. Gastroenterology 2004; 126: 1122-33.

  50. Nakatani T, Kuriyama S, Tominaga K, Tsujimoto T, Mitoro A, Yamazaki M, Tsujinoue H, Yoshiji H, Nagao S, Fukui H. Assessment of efficiency and safety of adenovirus mediated gene transfer into normal and damaged murine livers. Gut 2000; 47: 563-70.

  51. Dooley S, Hamzavi J, Breitkopf K, Wiercinska E, Said HM, Lorenzen J, Ten Dijke P, Gressner AM. Smad 7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology 2003; 125: 178-91.

  52. Arias M, Lehnen-Sauer S, Treptau J, Janoschek N, Theuerkauf I, Buettner R, Gressner A, Weiskirchen R. Adenoviral expression of a TGF-b1 antisense mRNA is effective in preventing liver fibrosis in bile-duct ligated rats. BMC Gastroenterology 2003; 3: 29.

  53. Suzuki K, Aoki K, Ohnami S, Yoshida K, Kazui T, Kato N, Inoue K, Kohara M, Yoshida T. Adenovirus-mediated gene transfer of interferon alpha improves dimethylnitrosamine-induced liver cirrhosis in rat model. Gene Ther 2003; 10: 765-73.

  54. Gupta M, Janses EE, Senephansiri H, Jakobs C, Snead OC, Grompe M, Gibosn KM. Liver-directed adenoviral gene transfer in murine succinate semialdehyde dehydrogenase deficiency. Mol Ther 2004; 9: 527-39.

  55. Miranda-Díaz A, Rincón A, Salgado S, Vera-Cruz J, Gálvez J, Islas MC, Berumen J, Aguilar-Cordova E, Armendáriz-Borunda J. Improved effects of viral gene delivery of human uPA plus biliodigestive anastomosis induce recovery from experimental biliary cirrhosis. Molecular Therapy 2004; 9: 30-7.

  56. Zaratiegui M, Castilla-Cortazar I, García M, Quiroga J, Prieto J, Novo FJ. IGF-1 gene transfer into eskeletal muscle using recombinant adeno-associated virus in a rat model of liver cirrosis. J Physiol Biochem 2002; 58(3): 169-76.

  57. High KA, Herzog R, Arruda V. AAV-mediated gene transfer to liver. Blood; 101: 333-3339.




2020     |     www.medigraphic.com